News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Drug Flops From 2004 Haunt AstraZeneca PLC (AZN) Investors



5/23/2014 7:56:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, May 20 (Reuters) - AstraZeneca's confidence in its promising new drugs may have seen off Pfizer's $118 billion takeover bid for now, but investors are left contemplating the lessons from 2004, when it was also trumpeting its product pipeline. AstraZeneca became renowned a decade ago for talking up the prospects for its new treatments under former chief executive Tom McKillop, only to see key experimental medicines tumble like ninepins in a series of development setbacks.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES